TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04587687: Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Sponsor: University of California, Davis · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 23 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT04587687 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04587687 Rescue Dossier →